ETNK1

Across TCGA pan-cancer cohorts, ETNK1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ETNK1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ETNK1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ETNK1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ETNK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.903	0.503	.003	53	view →
LUAD	DFS	Median	II,III,IV	0.212	0.788	.002	25	view →
CCRCC	DFS	Tertile	III,IV	0.344	0.667	.005	16	view →
HNSC	OS	Median	All	0.449	1.000	.023	10	view →
GBM	DFS	Median	All	0.855	0.636	.002	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ETNK1–PDAC (DFS)

Open the PDAC breakdown →